Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e222735-e222735
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
Gavin Y. Oudit, Kaiming Wang, Anissa Viveiros, et al.
Cell (2023) Vol. 186, Iss. 5, pp. 906-922
Open Access | Times Cited: 74
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, et al.
JAMA (2023) Vol. 329, Iss. 14, pp. 1183-1183
Open Access | Times Cited: 45
Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 17
Open Access | Times Cited: 44
Mechanisms of COVID-19 pathogenesis in diabetes
Chandrakala Aluganti Narasimhulu, Dinender K. Singla
AJP Heart and Circulatory Physiology (2022) Vol. 323, Iss. 3, pp. H403-H420
Open Access | Times Cited: 42
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs, et al.
JAMA (2023) Vol. 329, Iss. 14, pp. 1170-1170
Open Access | Times Cited: 29
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
Microvascular significance of TGF-β axis activation in COVID-19
Lauren M. Arguinchona, Caterina Zagona‐Prizio, Megan E. Joyce, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access | Times Cited: 18
Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment
Mark C. Chappell
Circulation Research (2023) Vol. 132, Iss. 10, pp. 1320-1337
Open Access | Times Cited: 17
Characterizing temporal and global host innate immune responses against SARS-CoV-1 and -2 infection in pathologically relevant human lung epithelial cells
Vivian Tat, Aleksandra Drelich, Pinghan Huang, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0317921-e0317921
Open Access
Modulation of the Renin-Angiotensin System against COVID-19: A path forward?
Serge Camelo, Waly Dioh, J. Pedro Teixeira, et al.
International Journal of Infectious Diseases (2025), pp. 107867-107867
Open Access
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
Meg Jardine, Sradha Kotwal, Abhinav Bassi, et al.
BMJ (2022), pp. e072175-e072175
Open Access | Times Cited: 24
Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review
Carles Vilaplana-Carnerero, Maria Giner‐Soriano, Ángela Domı́nguez, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1206-1206
Open Access | Times Cited: 14
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
Daniel E. Leisman, Damian Handisides, Lakhmir S. Chawla, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial
Robert A. Wise, Janet T. Holbrook, Robert H. Brown, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 206, Iss. 7, pp. 838-845
Open Access | Times Cited: 21
Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
Vasiliki Tsampasian, Natasha Corballis, Vassilios S. Vassiliou
Current Hypertension Reports (2022) Vol. 24, Iss. 10, pp. 425-433
Open Access | Times Cited: 19
Effects of Losartan on Patients Hospitalized for Acute Coronavirus Disease 2019: A Randomized Controlled Trial
Karen Tran, Pierre Asfar, Matthew P. Cheng, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 3, pp. 615-625
Closed Access | Times Cited: 3
The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure
Fabio Angeli, Martina Zappa, Gianpaolo Reboldi, et al.
European Journal of Internal Medicine (2022) Vol. 109, pp. 12-21
Open Access | Times Cited: 17
Standard of care plus telmisartan on respiratory failure due to COVID-19 (STAR-COVID trial)
Abraham Edgar Gracia‐Ramos, Gissel Y. ÁNGELES-DURÁN, Iván R. Flores-Gómez, et al.
Minerva Cardiology and Angiology (2024) Vol. 72, Iss. 2
Closed Access | Times Cited: 2
Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease
M. Balasubramanian, Anupriya M. Geethakumari, Ramya Ramadoss, et al.
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1754-1754
Open Access | Times Cited: 12
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
Rodolfo Pedro Rothlin, Facundo Pelorosso, Mariano Duarte, et al.
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 5
New insights into kidney disease after COVID-19 infection and vaccination: histopathological and clinical findings
Yebei Li, Yan Gong, Gaosi Xu
QJM (2023) Vol. 117, Iss. 5, pp. 317-337
Closed Access | Times Cited: 5
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
Matthew M.Y. Lee, Toru Kondo, Ross T. Campbell, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 68-80
Open Access | Times Cited: 5
How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection
Kajetan Kiełbowski, Mariola Herian, Andrzej Pawlik
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6377-6377
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top